array:19 [
  "pii" => "X0211699500025533"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:59"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1429
    "formatos" => array:3 [
      "EPUB" => 156
      "HTML" => 988
      "PDF" => 285
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025525"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:60"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1505
      "formatos" => array:3 [
        "EPUB" => 145
        "HTML" => 1098
        "PDF" => 262
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "The Controversies of Hyperuricemia And its Role in Renal Disease and Hypertension"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "60"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R. J. JOHNSON"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "R. J. JOHNSON"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025525?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025525/v0_201502091333/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025541"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:58"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4710
      "formatos" => array:3 [
        "EPUB" => 181
        "HTML" => 3907
        "PDF" => 622
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "¿Cuál es el papel de los calcioantagonistas (CaA) en el tratamiento de la HTA asociada a la enfermedad renal?"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "58"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. HERRERA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. HERRERA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025541?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025541/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "The renoprotective actions of angiotensin converting enzyme inhibitors in non diabetic proteinuric nephropathies"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "59"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "P. RUGGENENTI"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "P. RUGGENENTI"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 The renoprotective actions of angiotensin converting enzyme inhibitors in non diabetic proteinuric nephropathies P. Ruggenenti Negui Bergamo Laboratories. Italy. Chronic renal disease evolves to end-stage renal disease (ESRD) through a series of events that cause progressive parenchymal damage, which appears relatively independent of the initial insult. While the mechanisms underlying this process remain ill defined, the key lesion common to renal diseases of various etiologies is the sclerosis of the glomerular tuft. When the glomerular injury involves a critical number of nephrons, the disease progresses to terminal renal failure. Of the several theories that can explain the cause of renal disease progression, the most accredited one suggests a key role of an increase in glomerular perfusion pressure in remnant nephrons after a critical portion of renal parenchyma is lost. Intracapillary hypertension may increase glomerular ultrafiltration of plasma proteins which, in turn, may habe an intrinsic renal toxicity. Among mediators of renal disease progression, angiotensin II seems to play a fundamental role in sustaining glomerular hemodynamic changes and loss of permselective function. Thus, blockade of the renin-angiotensin-system is likely critical for preventing or modulating progressive renal damage in chronic nephropathies. Indeed, angiotensin-converting-enzyme (ACE) inhibitors have been consistently reported to have a specific renoprotective effect in diabetics and non-diabetic nephropathies. In particular, the Ramipril Efficacy Correspondence: P. Ruggenenti, M. D. Negri Bergamo Laboratories Via Gavazzeni, 11 24125 Bergamo - ITALY Phone: +39-035-319888 Fax: +39-035-319331 In Nepropathy (REIN) study found that ACE inhibitors may halve the rate of progression to ESRD and even halt GFR decline in patients with proteinuric chronic nephropathies. However, although ACE inhibitors are the best therapy available to date for animal and human proteinuric progressive nephropathies, alone they are not always sufficient to normalise urinary proteins or to fully prevent renal damage and GFR decline. Thus, either in diabetic and non-diabetic chronic nephropathies, ACE inhibitors may reduce proteinuria by 20% to 80%, depending on the dose and length of treatment. Thus, other treatments might synergize with ACE inhibitors in further limiting protein traffic and/or interfering with events by which tubular reabsorption of filtered proteins translates into interstitial inflammation and structural damage. Multi drug approach might be targeted to: 1. maximise the response to ACE inhibitors by low sodium diet, diuretics, and intensified blood pressure control. 2. amplify the antiproteinuric effect of ACE inhibitors by the concomitant use of diverse antiproteinuric compounds which may include angiotensin II receptor antagonists (AII antagonists), non-dihydropyridine type calcium channel blockers (CCBs), and non-steroidal anti inflammatory drugs (NSAID). 3. target, by endothelin receptor antagonists, for example, one of the most important vasoactive and inflammatory mediators which are upregulated by proximal tubular cells activated by protein overload. Hoperfully, as in the past multi drug treatments allowed the oncologists to induce remission even of apparently hopeless cases, in the forthcoming years a similar approach will allow nephrologists to halt disease evolution even in most rapidly progressing nephropathies. 59 "
    "pdfFichero" => "P7-E170-S140-A1901.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025533/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025533/v0_201502091333/en/P7-E170-S140-A1901.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025533?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

The renoprotective actions of angiotensin converting enzyme inhibitors in non diabetic proteinuric nephropathies
P. RUGGENENTI
Leído
3767
Veces
se ha leído el artículo
1557
Total PDF
2210
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699500025533"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:59"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1429
    "formatos" => array:3 [
      "EPUB" => 156
      "HTML" => 988
      "PDF" => 285
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025525"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:60"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1505
      "formatos" => array:3 [
        "EPUB" => 145
        "HTML" => 1098
        "PDF" => 262
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "The Controversies of Hyperuricemia And its Role in Renal Disease and Hypertension"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "60"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R. J. JOHNSON"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "R. J. JOHNSON"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025525?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025525/v0_201502091333/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025541"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:58"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4710
      "formatos" => array:3 [
        "EPUB" => 181
        "HTML" => 3907
        "PDF" => 622
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "¿Cuál es el papel de los calcioantagonistas (CaA) en el tratamiento de la HTA asociada a la enfermedad renal?"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "58"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. HERRERA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. HERRERA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025541?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025541/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "The renoprotective actions of angiotensin converting enzyme inhibitors in non diabetic proteinuric nephropathies"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "59"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "P. RUGGENENTI"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "P. RUGGENENTI"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 The renoprotective actions of angiotensin converting enzyme inhibitors in non diabetic proteinuric nephropathies P. Ruggenenti Negui Bergamo Laboratories. Italy. Chronic renal disease evolves to end-stage renal disease (ESRD) through a series of events that cause progressive parenchymal damage, which appears relatively independent of the initial insult. While the mechanisms underlying this process remain ill defined, the key lesion common to renal diseases of various etiologies is the sclerosis of the glomerular tuft. When the glomerular injury involves a critical number of nephrons, the disease progresses to terminal renal failure. Of the several theories that can explain the cause of renal disease progression, the most accredited one suggests a key role of an increase in glomerular perfusion pressure in remnant nephrons after a critical portion of renal parenchyma is lost. Intracapillary hypertension may increase glomerular ultrafiltration of plasma proteins which, in turn, may habe an intrinsic renal toxicity. Among mediators of renal disease progression, angiotensin II seems to play a fundamental role in sustaining glomerular hemodynamic changes and loss of permselective function. Thus, blockade of the renin-angiotensin-system is likely critical for preventing or modulating progressive renal damage in chronic nephropathies. Indeed, angiotensin-converting-enzyme (ACE) inhibitors have been consistently reported to have a specific renoprotective effect in diabetics and non-diabetic nephropathies. In particular, the Ramipril Efficacy Correspondence: P. Ruggenenti, M. D. Negri Bergamo Laboratories Via Gavazzeni, 11 24125 Bergamo - ITALY Phone: +39-035-319888 Fax: +39-035-319331 In Nepropathy (REIN) study found that ACE inhibitors may halve the rate of progression to ESRD and even halt GFR decline in patients with proteinuric chronic nephropathies. However, although ACE inhibitors are the best therapy available to date for animal and human proteinuric progressive nephropathies, alone they are not always sufficient to normalise urinary proteins or to fully prevent renal damage and GFR decline. Thus, either in diabetic and non-diabetic chronic nephropathies, ACE inhibitors may reduce proteinuria by 20% to 80%, depending on the dose and length of treatment. Thus, other treatments might synergize with ACE inhibitors in further limiting protein traffic and/or interfering with events by which tubular reabsorption of filtered proteins translates into interstitial inflammation and structural damage. Multi drug approach might be targeted to: 1. maximise the response to ACE inhibitors by low sodium diet, diuretics, and intensified blood pressure control. 2. amplify the antiproteinuric effect of ACE inhibitors by the concomitant use of diverse antiproteinuric compounds which may include angiotensin II receptor antagonists (AII antagonists), non-dihydropyridine type calcium channel blockers (CCBs), and non-steroidal anti inflammatory drugs (NSAID). 3. target, by endothelin receptor antagonists, for example, one of the most important vasoactive and inflammatory mediators which are upregulated by proximal tubular cells activated by protein overload. Hoperfully, as in the past multi drug treatments allowed the oncologists to induce remission even of apparently hopeless cases, in the forthcoming years a similar approach will allow nephrologists to halt disease evolution even in most rapidly progressing nephropathies. 59 "
    "pdfFichero" => "P7-E170-S140-A1901.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025533/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025533/v0_201502091333/en/P7-E170-S140-A1901.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025533?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 5 11 16
2024 Octubre 29 33 62
2024 Septiembre 35 29 64
2024 Agosto 50 48 98
2024 Julio 31 32 63
2024 Junio 33 19 52
2024 Mayo 37 30 67
2024 Abril 29 27 56
2024 Marzo 22 25 47
2024 Febrero 28 33 61
2024 Enero 16 17 33
2023 Diciembre 20 26 46
2023 Noviembre 16 26 42
2023 Octubre 21 27 48
2023 Septiembre 21 24 45
2023 Agosto 22 29 51
2023 Julio 25 26 51
2023 Junio 31 25 56
2023 Mayo 30 27 57
2023 Abril 13 10 23
2023 Marzo 14 14 28
2023 Febrero 22 18 40
2023 Enero 24 16 40
2022 Diciembre 27 19 46
2022 Noviembre 20 20 40
2022 Octubre 33 38 71
2022 Septiembre 27 24 51
2022 Agosto 26 30 56
2022 Julio 29 37 66
2022 Junio 31 21 52
2022 Mayo 18 31 49
2022 Abril 26 34 60
2022 Marzo 20 32 52
2022 Febrero 27 30 57
2022 Enero 20 27 47
2021 Diciembre 16 34 50
2021 Noviembre 21 28 49
2021 Octubre 29 37 66
2021 Septiembre 12 19 31
2021 Agosto 17 20 37
2021 Julio 14 28 42
2021 Junio 9 16 25
2021 Mayo 21 15 36
2021 Abril 23 34 57
2021 Marzo 18 12 30
2021 Febrero 16 15 31
2021 Enero 12 16 28
2020 Diciembre 16 9 25
2020 Noviembre 7 8 15
2020 Octubre 10 4 14
2020 Septiembre 6 5 11
2020 Agosto 23 6 29
2020 Julio 10 7 17
2020 Junio 8 8 16
2020 Mayo 12 9 21
2020 Abril 21 11 32
2020 Marzo 11 8 19
2020 Febrero 23 14 37
2020 Enero 25 15 40
2019 Diciembre 11 10 21
2019 Noviembre 8 2 10
2019 Octubre 5 8 13
2019 Septiembre 11 20 31
2019 Agosto 8 9 17
2019 Julio 7 11 18
2019 Junio 5 9 14
2019 Mayo 9 22 31
2019 Abril 27 25 52
2019 Marzo 11 9 20
2019 Febrero 4 11 15
2019 Enero 11 7 18
2018 Diciembre 18 16 34
2018 Noviembre 16 5 21
2018 Octubre 21 6 27
2018 Septiembre 23 9 32
2018 Agosto 15 4 19
2018 Julio 13 5 18
2018 Junio 14 6 20
2018 Mayo 11 8 19
2018 Abril 18 2 20
2018 Marzo 11 4 15
2018 Febrero 16 3 19
2018 Enero 13 3 16
2017 Diciembre 17 5 22
2017 Noviembre 12 3 15
2017 Octubre 12 5 17
2017 Septiembre 9 3 12
2017 Agosto 16 8 24
2017 Julio 8 3 11
2017 Junio 13 3 16
2017 Mayo 7 0 7
2017 Abril 8 1 9
2017 Marzo 6 6 12
2017 Febrero 6 1 7
2017 Enero 3 3 6
2016 Diciembre 11 2 13
2016 Noviembre 14 1 15
2016 Octubre 30 2 32
2016 Septiembre 18 2 20
2016 Agosto 43 2 45
2016 Julio 38 0 38
2016 Junio 53 0 53
2016 Mayo 62 0 62
2016 Abril 11 0 11
2016 Marzo 23 0 23
2016 Febrero 28 0 28
2016 Enero 12 0 12
2015 Diciembre 43 0 43
2015 Noviembre 26 0 26
2015 Octubre 31 0 31
2015 Septiembre 29 0 29
2015 Agosto 19 0 19
2015 Julio 18 0 18
2015 Junio 7 0 7
2015 Mayo 13 0 13
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?